Seizures Pipeline Insights, 2017: Monotherapy, Combination Products, Molecule Type & Route of Administration - Research & Mar...
January 23 2017 - 11:36AM
Business Wire
Research and Markets has announced the addition of the "Seizures
- Pipeline Insights, 2017" report to their offering.
Seizures - Pipeline Insights, 2017 provides in depth insights on
the pipeline drugs and their development activities around the
Seizures.
The This report covers the product profiles in various stages of
development including Discovery, Pre - clinical, IND, Phase I,
Phase II, Phase III and Preregistration.
Report covers the product clinical trials information and other
development activities including technology, licensing,
collaborations, acquisitions, fundings, patent and USFDA & EMA
designations details.
This report also provides detailed information on the
discontinued and dormant drugs that have gone inactive over the
years for Seizures.
This report also assesses the Seizures therapeutics by
Monotherapy, Combination products, Molecule type and Route of
Administration.
Key Topics Covered:
- Seizures Overview
- Seizures Disease Associated
- Seizures Pipeline Therapeutics
- Seizures Therapeutics under Development by Companies
- Seizures Filed and Phase III Products
- Seizures Phase II Products
- Seizures Phase I and IND Filed Products
- Seizures Discovery and Pre-Clinical Stage Products
- Drug Candidate Profiles
- Seizures - Therapeutics Assessment
- Seizures - Discontinued Products
- Seizures - Dormant Products
- Companies Involved in Therapeutics Development for
Seizures
- Appendix
For more information about this report visit
http://www.researchandmarkets.com/research/bdzdk5/seizures
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170123005741/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Related Topics: Central Nervous System
Drugs